Multidrug resistance-modifying components in human plasma with potential clinical significance

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 1, 1996, Pages 13-22

  Mulder H S ^a   Pinedo, H M ^a   Timmer, A T ^a   Ramanath Rao, B ^a   Lankelma, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human plasma; MRP; Multidrug resistance; P gp

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; GLYCOPROTEIN P; HYDROCORTISONE; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD; CELL CULTURE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; PH;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROCORTISONE; HYDROGEN-ION CONCENTRATION; MALE; MASS SPECTROMETRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0029677435     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Broxterman HJ, Pinedo HM. Energy-metabolism in multidrug-resistant tumor cells: a review. J Cell Pharmacol 2: 239-247, 1991.
4. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
5. Zaman GJR, Flens MJ, Van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci (USA) 91: 8822-8826, 1994.
6. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep 67: 889-894, 1983.
7. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635, 1993.
8. Broxterman HJ, Jansen G, Linn SC, Lankelma J. The impact of transport-associated resistance in anticancer chemotherapy. In: Georgopapadakou NH, (ed). Drug transport in antimicrobial and anticancer chemotherapy, New York: Marcel Dekker Inc., 21-62, 1995.
9. Ichikawa-Haraguchi M, Sumizawa T, Yoshimura A, Furukawa T, Hiramoto S, Sugita M, Akiyama S. Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim Biophys Acta 1158: 201-208, 1993.
10. Yang CH, Goei Depinho S, Greenberger L M, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788, 1989.
11. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67: 284-289, 1993.
12. Wolf DC, Horwitz SB. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 52: 141-146, 1992.
13. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252, 1992.
14. Van der Valk P, Van Kalken CK, Ketelaars H, et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1: 56-64, 1990.
15. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Akiyama S. Modulators of the multidrug-transporter, P-glycoprotein, exist in the human plasma. Biochem Biophys Res Commun 166: 74-80, 1990.
16. Kuiper CM, Broxterman HJ, Baas F, et al. Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35-41, 1990.
17. Zaman GJR, Versantvoort CHM, Smit JJM, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
18. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Van der Hoeven JJM, Pinedo HM, Lankelma J. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: Role of protein binding. Cancer Lett 35: 87-95, 1987.
19. Mosmann T. Rapid colometric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63, 1983.
20. Mülder HS., Dekker H, Pinedo HM, Lankelma J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines varying in lipophilicity. Biochem Pharmacol 50: 967-974, 1995
21. Mülder HS, Lankelma J, Dekker H, Pinedo HM. Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug resistant lung-cancer cells. Int J Cancer 59: 275-281, 1994.
22. Ruder HJ, Guy RL, Lipsett MB. A radioimmunoassay for cortisol in plasma and urine. J Clin Endocrinol 35: 219-224, 1972.
23. Eksborg S, Ehrsson, H, Ekqvist B. Protein binding of anthraquinone glycosides, with special reference to adriamycin. Cancer Chemother Pharmacol 10: 7-10, 1982.
24. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43: 3417-3421, 1983.
25. Versantvoort CHM, Broxterman HJ, Feller N, Dekker H, Kuiper CM, Lankelma J. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 50: 906-911, 1992.
26. Spoelstra EC, Westerhoff HV, Dekker H, Lankelma J. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur J Biochem 207: 567-579, 1992.
27. Qian X, Beck WT. Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem 265: 18753-18756, 1990.
28. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48: 287-292, 1994.
29. Altuvia S, Stein WD, Goldenberg S, Kane S, Pastan I, Gottesman MM. Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 268: 27127-27132, 1993.
30. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, Dickson RB. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 84: 1506-1512, 1992.
31. Bondy PK. Disorders of the adrenal cortex. In: Wilson JD, Foster DW, (eds), Williams textbook of Endocrinology, 7th ed., Philadelphia: Saunders, 817-890, 1985.
32. Mickelson KE, Harding GB, Forsthoefel M, Westphal U. Steroid-protein interactions. Human corticosteroid-binding globulin: characterization of dimer and electrophoretic variants. Biochemistry 21: 654-660, 1982.
33. Krieger DT. Plasma ACTH and Cortocosteroids. In: DeGroot LJ, (ed.), Endocrinology 2nd ed., New York: Grune and Stratton, 1139-1156, 1979.
34. Dalton WS. Overcoming the multidrug-resistant phenotype. In: De Vita VT, Hellman S, Rosenberg SA, (eds), Cancer: Principles & Practice of Oncology, New York: JB Lippincott Co, 2655-2666, 1993.
35. Rosen F, Talley RW. Corticosteroids. In: Holland JF, Fre E, (eds), Cancer Medicine, Philadelphia: Lea & Febier, 994-1008, 1982.
36. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1358, 1984.
37. Reynolds JEF. Corticosteroids. In: Reynolds JEF, (ed.), Martindale: The Extra Pharmacopoeia, thirtieth edition, London: The Pharmaceutical Press, 712-740, 1993.
38. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopietic stem cells. Cell 66: 85-94, 1991.
39. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994.
40. Hrushesky WJM. Circadian timing of cancer chemotherapy. Science 228: 73-75, 1985.
41. Pinedo HM, Giaccone G. P-glycoprotein as a marker of biological behaviour. N Eng J Med (in press).